There is evidence indicating that a consequence of advanced NAFLD (non-alcoholic steatohepatitis [NASH]) includes enhanced atherosclerosis via further insulin resistance leading to atherogenic hyperlipidaemia (low HDL-cholesterol, high triacylglycerol and high LDL-cholesterol levels) and systemic inflammation through pro-inflammatory and pro-atherogenic factors (IL-6, TNF-α, nuclear factor kappa-light-chain-enhancer of activated B cells [6, 7]). The gene discussed is IL6; the disease is metabolic dysfunction-associated steatohepatitis.